RT Journal Article
SR Electronic
T1 Impact of the MyProstateScore (MPS) test on the clinical decision to undergo prostate biopsy: results from a contemporary academic practice
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.17.20036384
DO 10.1101/2020.03.17.20036384
A1 Lebastchi, Amir H.
A1 Russell, Christopher M.
A1 Niknafs, Yashar S.
A1 Eyrich, Nicholas W.
A1 Chopra, Zoey
A1 Botbyl, Rachel
A1 Kabeer, Rana
A1 Osawa, Takahiro
A1 Siddiqui, Javed
A1 Siddiqui, Rabia
A1 Davenport, Matthew S.
A1 Mehra, Rohit
A1 Tomlins, Scott A.
A1 Kunju, Lakshimi P.
A1 Chinnaiyan, Arul M.
A1 Wei, John T.
A1 Tosoian, Jeffrey J.
A1 Morgan, Todd M.
YR 2020
UL http://medrxiv.org/content/early/2020/03/23/2020.03.17.20036384.abstract
AB Objective To evaluate the association of the MyProstateScore (MPS) urine test on the decision to undergo biopsy in men referred for prostate biopsy at a contemporary academic urology practice.Methods MPS testing was offered as an alternative to immediate biopsy in men referred to the University of Michigan for prostate biopsy from October 2013 through October 2016. The primary endpoint was the decision to perform biopsy. The proportion of patients who underwent biopsy was calculated across MPS quintiles and compared to predicted risk scores from the Prostate Cancer Prevention Trial risk calculator (PCPTrc). Analyses were performed in the overall referral population and the intended-use population (PSA 3-10 ng/ml or PSA <3 ng/ml and abnormal DRE) and stratified by the use of multiparametric magnetic resonance imaging (mpMRI). The associations of PCPTrc, MPS, and mpMRI with the decision to undergo biopsy were explored in a multivariable logistic regression model.Results Of 248 patients, 134 (54%) proceeded to prostate biopsy. Clinical variables, PSA, and PCPTrc score did not significantly differ based on the decision to undergo biopsy, while MPS was significantly higher in biopsied patients (median 29 vs. 14, p<0.001). The use of biopsy was strongly associated with MPS, with biopsy rates of 26%, 38%, 58%, 90%, and 85% in the first through fifth MPS quintiles, respectively (p<0.001). By contrast, biopsy rates were 51%, 47%, 52%, 69%, and 52% by increasing PCPTrc score quintile (p=0.3). The association of MPS with biopsy persisted upon stratification by use of mpMRI. On multivariable analysis, MPS was strongly associated with the decision to undergo biopsy when modeled as both a continuous variable (odds ratio [OR] 1.05 per 1 unit increase, 95% confidence interval [CI] 1.04-1.08; <0.001) and binary variable (OR 7.76, 95% CI 4.14-14.5; p<0.001). These findings were consistent in the overall and intended-use populations.Conclusion In a cohort of patients who underwent clinical MPS testing as an alternative to immediate prostate biopsy, 46% were able to avoid biopsy and increasing MPS was strongly associated with biopsy rates. These findings were robust to the use of mpMRI and consistent across pertinent subpopulations. Overall, these data suggest that the MPS assay may substantially reduce the number of men undergoing prostate needle biopsy.Competing Interest StatementJJT, YSN, and AMC are co-founders and have equity in Lynx Dx, which has licensed the urine biomarkers mentioned in this study from Hologic and the University of Michigan. JJT and YSN have leadership roles in Lynx Dx. The University of Michigan has been issued a patent on ETS gene fusions in prostate cancer on which AMC and SAT are co-inventors. The diagnostic field of use has been licensed to Lynx Dx. SAT serves as CMO of Strata Oncology which was not involved in this study. Lynx Dx or Strata Oncology did not fund the conduct of this study.Clinical TrialThis was an institutional review board-approved retrospective analysis evaluating the impact of a clinically-available test on clinical decision making. Thus it was not a prospectively registered trial.Funding StatementJJT is supported by the National Institutes of Health/National Cancer Institute Advanced Training in Urologic Oncology Grant (T32/CA180984). His research is funded in part by an award from the SPORE Career Enhancement Program (CA186786). AMC is a Howard Hughes Medical Institute Investigator and an American Cancer Society Research Professor. This work was supported by the Prostate Cancer Foundation, Early Detection Research Network (UO1 CA214170), NCI Prostate SPORE (P50 CA186786), and an NCI Outstanding Investigator Award (R35CA231996). TMM is supported by the A. Alfred Taubman Medical Research Institute. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData associated with article can be provided on request. Please contact the corresponding author.